Alzamend Neuro Files 8-K
Ticker: ALZN · Form: 8-K · Filed: Jul 31, 2024 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | 8-K |
| Filed Date | Jul 31, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financials, disclosure
TL;DR
Alzamend Neuro dropped an 8-K on 7/31 - check financials and Reg FD.
AI Summary
Alzamend Neuro, Inc. filed an 8-K on July 31, 2024, reporting on financial statements and exhibits, and a Regulation FD Disclosure. The company, incorporated in Delaware, has its principal executive offices in Atlanta, GA.
Why It Matters
This filing provides important updates and disclosures for investors regarding Alzamend Neuro's financial status and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing for an 8-K, primarily containing financial statements and exhibits, with no immediate indication of significant negative events.
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- July 31, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Atlanta, GA (location) — Address of principal executive offices
FAQ
What specific financial statements are included in this 8-K filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific details of these statements are not provided in the provided text.
What is the purpose of the Regulation FD Disclosure mentioned in the filing?
The Regulation FD Disclosure item suggests the company is providing information to ensure fair and widespread disclosure of material non-public information.
When was Alzamend Neuro, Inc. incorporated?
The filing states that the company's state of incorporation is Delaware.
What is the primary business of Alzamend Neuro, Inc. according to the SIC code?
The Standard Industrial Classification (SIC) code provided is 2834, which corresponds to 'Pharmaceutical Preparations'.
What is the contact phone number for Alzamend Neuro, Inc.?
The registrant's telephone number, including area code, is (844) 722-6333.
Filing Stats: 974 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2024-07-31 16:30:22
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value ALZN The Nasdaq Capital M
- $1.00 — Company's common stock had closed below $1.00 per share (the " Minimum Bid Requiremen
Filing Documents
- o7302498k.htm (8-K) — 30KB
- ex99_1.htm (EX-99.1) — 8KB
- alzamendlogo_sm.jpg (GRAPHIC) — 18KB
- 0001214659-24-013382.txt ( ) — 239KB
- alzn-20240731.xsd (EX-101.SCH) — 3KB
- alzn-20240731_lab.xml (EX-101.LAB) — 33KB
- alzn-20240731_pre.xml (EX-101.PRE) — 22KB
- o7302498k_htm.xml (XML) — 4KB
01 Regulation
Item 7.01 Regulation FD Disclosure As previously reported under Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing), on February 1, 2024, Alzamend Neuro, Inc. (the " Company ") received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (" Nasdaq ") notifying the Company that, for 30 consecutive business days, the bid price for the Company's common stock had closed below $1.00 per share (the " Minimum Bid Requirement ") and that the Company had 180 calendar days to regain compliance with the Minimum Bid Requirement. On July 30, 2024, the Company received notice from Nasdaq that the Company has regained compliance with the Minimum Bid Price Requirement and stated that the matter is now closed. On July 31, 2024, the Company issued a press release to announce that the Company has regained compliance with the Minimum Bid Price Requirement. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. Disclosure Channels The Company wishes to notify the investment community and others that in the future, it may choose to communicate material information about the Company and its business and for complying with the Company's disclosure obligation under Regulation FD via social media channels. The Company has identified its social media channels for material information as follows: Facebook: facebook.com/AlzamendNeuro Instagram: instagram.com/alzamendneuro LinkedIn: linkedin.com/company/alzamend-neuro Threads: threads.net/@alzamendneuro TikTok: tiktok.com/@alzamendneuro X (f/k/a Twitter): x.com/alzamendneuro YouTube: youtube.com/@alzamendneuroinc.9277 The information the Company posts through these social media channels may be deemed material. Accordingly, investors should monitor these social media channels in addition to the information that the Company discloses using its investors tab page on
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits: Exhibit No. Description 99.1 Press Release dated July 31, 2024 101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALZAMEND NEURO, INC. Dated: July 31, 2024 /s/ Stephan Jackman Stephan Jackman Chief Executive Officer -3-